Table 1.
Summary of studies included (N = 24)
| Characteristic | n (%) |
|---|---|
| Study design | |
| Quantitative | 22 (91.7) |
| Cross-sectional | 13 (54.2) |
| Longitudinal | 3 (12.5) |
| Quasi-experimental | 2 (8.3) |
| Retrospective | 4 (16.7) |
| Mixed methods | 2 (8.3) |
| Sample size | |
| None given | 1 (4.2) |
| 1–100 | 7 (29.2) |
| 101–1000 | 10 (41.6) |
| > 1000 | 6 (25.0) |
| Region (as defined by WHO) | |
| Africa | 1 (4.2) |
| Americas | 11 (45.8) |
| South-East Asia | 1 (4.2) |
| Europe | 5 (20.8) |
| Eastern Mediterranean | 0 (0.0) |
| Western Pacific | 2 (8.3) |
| Global | 2 (8.3) |
| Respiratory epidemic | |
| COVID-19 | 24 (100) |
| Primary SRH outcomea | |
| Abortion | 8 (33.3) |
| Contraceptive access/utilization | 5 (20.8) |
| Menstruation | 2 (8.3) |
| Service provision | 6 (25.0) |
| Sexual behavior | 4 (16.7) |
| Pregnancy intentions | 3 (12.5) |
| QATSDD | |
| High | 10 (41.7) |
| Low | 14 (58.3) |
SRH sexual and reproductive health; COVID-19 coronavirus disease 2019, WHO World Health Organization; QATSDD Quality Assessment Tool for Studies with Diverse Designs
aMay not equate to 100% due to multiple outcomes